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Abstract. 
 20 
The purpose of this work was to evaluate gas perfusion isothermal calorimetry (ITC) as a 
method to characterize the physicochemical changes of active pharmaceutical ingredients 
(APIs) intended to be formulated in pressurised metered dose inhalers (pMDIs) after 
exposure to a model propellant.  Spray dried samples of beclomethasone dipropionate (BDP) 
and salbutamol sulphate (SS) were exposed to controlled quantities of 2H,3H-25 
decafluoropentane (HPFP) to determine whether ITC could be used as a suitable analytical 
method for gathering data on the behavioural properties of the powders in real time. The 
crystallization kinetics of BDP and the physiochemical properties of SS were successfully 
characterized using ITC and supported by a variety of other analytical techniques. 
Correlations between real and model propellant systems were also established using 30 
hydrofluoroalkane (HFA-227) propellant.  In summary, ITC was found to be suitable for 
gathering data on the crystallization kinetics of BDP and SS. In a wider context, this work 
will have implications on the use of ITC for stability testing of APIs in HFA-based pMDIs.   
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1. Introduction 
Since the introduction of the first commercially available hydrofluoroalkane (HFA) 35 
pressurized metered dose inhaler (pMDI) in 1994(1), significant progress has been made in 
understanding the fundamental interactions between active pharmaceutical ingredients (API) 
and hydrofluoroalkane propellants, namely HFA 134a and HFA 227.  Understanding the 
relationship between HFAs and active pharmaceutical ingredients (APIs) used for inhalation 
formulations is pivotal to the design and performance of the final formulation. Many 40 
techniques have been employed in the past to study API stability in HFAs in terms of 
aerodynamic diameter and geometric particle size; including visual inspection of flocculated 
particles (2, 3), in vitro cascade impaction (4) and in situ laser diffraction to study particle 
growth (5).  High performance liquid chromatography (HPLC) methods have also been 
utilized to observe chemical stability of APIs exposed to propellants (3).  Although previous 45 
studies have provided some insight into the interactions of APIs in this medium, zeta 
potential, micelle formation and other physicochemical tests are more challenging to conduct, 
due to the volatile nature of HFAs at ambient pressure.  To compensate for this shortfall, a 
model propellant substitution 2H,3H-decafluoropentane, namely HPFP, which is liquid at 
ambient pressure, has been proposed to mimic the physiochemical properties of HFA 227 (6). 50 
 
This model propellant has previously been employed to study drug-HFA interactions. For 
example, atomic force microscopy techniques (7-10) have been conducted in which HPFP 
was utilised as a medium to further investigate cohesive drug-drug, drug-surfactant, drug-
propellant and drug-canister interaction forces.  A recent study by Bouhroum (11) has 55 
measured the adhesive forces between beclomethasone dipropionate (BDP) clathrates formed 
by trichlorofluoromethane and pMDI components in the presence of HPFP. HPFP has also 
been used as a surrogate for HFA to study particle stability of chitosan-sodium 
tripolyphosphate nanoparticles intended for the pulmonary delivery of nucleic acids (12).  
 60 
Isothermal calorimetry (ITC) is a quantitative physical technique used to determine reaction 
thermodynamics and kinetics. Being invariant to sample physical form, it can be used to 
study solutions, solids and heterogeneous mixtures and has been applied to many areas of 
pharmaceutical development, including pre-formulation stages of inhalation device 
development, determination of solubility (13), enthalpy of solution (14), percentage 65 
crystallinity (15) or amorphicity (16) and interactions between drug and carrier (17). The 
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high sensitivity of the technique means that ITC has potential to study complex drug-
propellant interactions, suited to API stability studies (18). 
 
Building on previous research (19), this study is designed to expand the use of ITC beyond 70 
using water or organic vapours.  Specifically, ITC was used to investigate physiochemical 
changes in API particles after exposure to HPFP. Spray dried samples of BDP and salbutamol 
sulphate (SS), two common drugs for inhalation with distinctively different properties and 
solubilities in HFA-227, were eluted with controlled volumes of HPFP to determine whether 
ITC is suitable for establishing information regarding the crystallization kinetics of inhalation 75 
powders in real-time.  In a wider context, the studies will have implications for the use of ITC 
for stability testing in HFA-
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2. Materials and Methods 
2.1 Materials. 
Beclomethasone dipropionate was supplied by Ai Radhe Sales (Gujarat, India). Salbutamol 80 
sulphate was supplied by Interchem (Chongqing, China).  Water was purified by reverse 
osmosis (MilliQ, Molsheim, France). All solvents were analytical grade and supplied by 
Sigma (Sydney, NSW, Australia). Propellant HFA-227 was supplied by Ineos Fluor Ltd. 
(Cheshire, UK). Metering valves (DF 31, nominal metered volume 50 µL) and actuators with 
orifice diameters of 0.3 mm, were supplied by Bespak Europe Limited (Norfolk, UK). Glass 85 
pMDI containers were supplied by Saint Gobain plc (London, UK). Aerosol formulations 
were pressure filled using a Pamasol Laboratory plant 02016 (pamasol W. Mäden AG, 
Pfäffikon, Switzerland).  
 
The model propellant 2H, 3H Decafluoropentane was supplied by Apollo Scientific, Cheshire, 90 
UK.  This was subsequently purified with chromatographic grade acidic and basic aluminium 
oxide (Fluka, Gillingham, UK) to remove impurities that could potentially alter 
measurements (7).  Approximately 400 g of acidic aluminium oxide was added to a sealed 
flask containing 2 L HPFP and agitated using the Ultrasonic Cleaner (Unisonics, Australia) 
for 45 min.  The resultant supernatant was vacuum filtered over a 0.2 µm PTFE to remove the 95 
aluminium oxide.  The filtrate was then added to an additional flask containing 
approximately 400 g of basic aluminium oxide.  This secondary mixture was again agitated 
using the Ultrasonic Cleaner for 45 min and the filtrate removed by vacuum filtration. HPFP 
was stored in capped laboratory bottles (Boeco, Germany), which contained approximately 
100g of 2 mm diameter molecular sieves (Sigma-Aldrich, Australia) to prevent moisture 100 
ingress.  
 
 
2.2. Preparation of BDP and SS micro-particulates. 
Beclomethasone diproprionate and salbutamol sulphate particles were prepared using a Mini 105 
Spray Dryer in closed loop configuration (Büchi, B-290, Switzerland). An ethanolic BDP 
solution (5% w/v) was spray-dried using the following parameters: inlet temperature 60°C, 
outlet temperature 43°C, feed rate 10% (2.5 mL min-1), 100% aspiration (40 m3.h-1) and an 
atomizing pressure of 742 kPa. An aqueous salbutamol sulphate solution (10% w/v) was 
spray dried using the following parameters: inlet temperature 150°C, outlet temperature 95°C, 110 
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feed rate 2% (0.5 mL.min-1), 100% aspiration (40 m3.h-1) and atomizing pressure of 742 kPa. 
The spray dried powders were stored at <10% RH and 25 °C, in tightly sealed containers, for 
>1 week prior to testing.   
 
2.3. Size Distribution. 115 
The particle size distributions of both BDP and SS were measured by laser diffraction 
(Malvern Mastersizer 2000, Malvern, Worcestershire, UK).  Approximately 5 mg of dry 
powder was introduced through a Scirocco dry feeder (Malvern, UK) and dispersed using 4-
bar pressure.  Samples were measured in triplicate at an obscuration between 3% and 10% 
with a refractive index of 1.564 and 1.553 for BDP and SS, respectively.  120 
 
2.4. Scanning Electron Microscopy and Focused Ion Beam Milling. 
The BDP and SS micro-particulates were imaged using FEI Quanta 200F (Oregon, USA),  
field-emission scanning electron microscopy (SEM) prior to and after being suspended in 
HPFP and HFA-227, respectively. Samples were deposited on sticky carbon tabs, mounted 125 
on SEM stubs and sputter coated (Quorum Q150, Kent, UK) on a tilt-rotating stage to 
achieve a 10 nm gold coating prior to SEM analysis and Focused Ion Beam (FIB) milling.  
Spray dried particles were then imaged at 5 kV. Focused Ion Beam milling of the samples 
was performed with a FIB-SEM dual beam system (Quanta 200 3D, FEI, USA). Micro-
particulate samples were milled at an accelerating voltage of 30 kV and a beam current of 25 130 
pA. Milling times for all samples were kept under 5 min. The samples were then examined 
using the SEM at 5 kV and tilted at 30° for visualization of the cross section.  
 
2.5. Specific Surface Area. 
The specific surface areas of the BDP and SS micro-particulates were measured using a 135 
Micromeritics Tristar II 3020 (GA, USA).  Prior to surface area analysis, the samples were 
degassed with N2 for 48 hr at 50°C.  Approximately 200 mg of sample were used for each 
experiment. Nitrogen adsorption isotherms were performed at relative pressures between 0.05 
and 0.3 at 77.3K and the surface area calculated according to the Brunauer−Emmett−Teller 
equation.  140 
 
2.6. Differential Scanning Calorimetry. 
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Thermal analysis of the BDP and SS micro-particulates, prior to and after 6 hrs exposure to 
HPFP vapour, was performed using differential scanning calorimetry (DSC Q2000, TA 
Instruments, Delaware, USA).  Approximately 4 mg of sample powder was weighed into 145 
non-hermetic T-zero Aluminium pans. All experiments were subject to a heating rate of 
10 °C min−1. The cell constant and enthalpy calibrations were performed with indium 
(Certified Reference Material LGC2601, Batch E1, LGC, London, Tm = 156.61oC, ∆Hf = 
28.70 J/g) in accordance with the manufacturer’s instructions. The measured values were in 
excellent agreement with those of the reference material (Tm ± 0.03oC, ∆Hf ± 0.1 J/g). 150 
Nitrogen (50 mL min-1) was used as a purge gas and data were analysed with Universal 
Analysis 2000 software (TA Instruments, Delaware, USA). Approximately 4 mg of each 
micronized drug was used as a standard to calculate crystalline percentages.   
 
2.7. Isothermal Calorimetry using HPFP. 155 
Calorimetric data was recorded using a 2277 Thermal Activity Monitor (TAM, 
Thermometric AB, Järfälla, Sweden) at 25°C.  Samples of each micro-particulate powder (20 
± 0.01 mg) were weighed directly into the stainless steel calorimetric ampoules. The 
ampoules were then attached to the gas perfusion accessory, the reservoirs of which had been 
filled with HPFP (0.9 mL). Mass flow controllers were used to quantitatively mix two gas 160 
streams flowing from different sources, one dry nitrogen line and one saturated with HPFP. 
The relative vapour pressure (RVP) in the sample ampoule could thus be altered in discrete 
steps (0% for 6 h, 90% for 3 h and finally 0% for 7 h). The immediate and primary advantage 
of this approach was that the flowing gas could be dry during the loading and equilibration 
phases; this ensures both that the water content of the sample at the start of each experiment 165 
is the same and that no information are lost prior to commencement of data capture. As HPFP 
was considerably more volatile than traditional solvents, HPFP reservoirs were freshly 
refilled and the RVP program repeated to assess any irreversible changes to the powder. Data 
were recorded every 10 s using the dedicated software package Digitam 4.1.  Experiments 
were performed in triplicate and at an amplifier range of 3000 µW. Power-time data was 170 
analysed using Origin (Microcal Software Inc., USA). 
 
2.8. Organic Dynamic Vapour Sorption.  
Organic Dynamic Vapour Sorption (O-DVS) measurements were performed to study the 
sorption properties of the powders.  Measurements were made with a DVS-1 (Surface 175 
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Measurement Systems, UK) at 25 °C using HPFP as the vapour probe. The operational set up 
of the O-DVS has been previously described (20).  Approximately 20 mg of either BDP or 
SS micro-particulates were weighed into the sample pan and exposed to a three-step HPFP 
partial pressure cycle of 0% - 90% following a protocol that matched the ITC measurements.  
 180 
2.9. X-Ray Powder Diffraction. 
The amorphous structure of the spray dried BDP and SS micro-particulates were 
characterised using X-ray powder diffraction (XRPD Siemens D6000 diffractometer, 
Siemens, Karlsruhe, Germany) at a scan range of 5–30°2θ, step size of 0.04° and count time 
of 2 s.  XRPD was also applied to both powders prior to and post exposure to HPFP vapour 185 
for 6 hours.  
 
2.10. Fourier Transform Infrared Spectroscopy. 
The samples were subjected to Fourier transform infrared (FT-IR) spectroscopy to assess any 
change in the BDP molecular state after elution with propellant vapour.  Samples of BDP 190 
were recorded with a PerkinElmer Spectrum 100 FTIR spectrometer in the wavenumber 
range of 650-4000 cm-1 with a resolution of 4 cm-1 at ambient conditions. 
 
3. Results & Discussion 
3.1. Physicochemical analysis of the spray-dried model drugs. 195 
Scanning electron microscopy images of the spray dried BDP and SS micro-particles are 
shown in Error! Reference source not found.Error! Reference source not found.Figure 
1A and B, respectively. The BDP particles had a smooth spherical geometry, with a size 
ranging from the submicron to around 4 µm. In comparison, SEM images of SS showed 
corrugated spherical particles with a similar size distribution to BDP.  In general, the SS 200 
morphology appeared to be similar to that reported in previous work, which utilised aqueous 
solutions to spray dry SS (21, 22); while the spray-dried BDP particles were similar in 
morphology to that reported by Abdel-Halim et al. (23), wherein particles were prepared 
from a 20% w/v ethanolic solution .  In general, both particulate systems could be considered 
of a suitable size for inhalation purposes (24), thus making the study of interactions in 205 
medical propellants relative to respiratory drug delivery. To study further the internal 
structure of these particles, focused ion beam microscopy was utilized to ‘dissect’ individual 
micron sized particles. In general, both particles were found to have a solid internal core 
9 
 
(Error! Reference source not found.Error! Reference source not found.Figure 1 right 
panel).  This solid internal core was an expected outcome due to the spray drying process, 210 
compared to the alternative technique of spray-freeze drying which can generate particles 
with a greater porosity (25, 26). 
 
Particle size distributions of the spray dried BDP and SS micro-particles are shown in Error! 
Reference source not found.Error! Reference source not found.Figure 2 and specific size 215 
parameters described in Table 1. It is important to note that the SS was significantly larger 
than BDP, however, both had considerable overlap in the volume of particles between 0.2 µm 
and 4 µm. Furthermore both BDP and SS had 100% particles < 10 µm and > 0.2 µm 
suggesting that these microparticles were comparable with respect to stability studies in 
HPFP.  220 
 
The difference in particle size distribution was further reflected in the apparent specific 
surface area, as measured by nitrogen adsorption experiments. The 5-point BET surface areas 
for BDP and SS were 4.55 ± 0.01 m²g-1 and 2.10 ± 0.02 m²g-1, respectively, reflecting the 
geometrically smaller spray dried BDP particles (yielding a surface area approximately 2.2 225 
larger that of the SS particles). Such observations are important since adsorption and 
absorption of HPFP onto/into the drug particle is a surface driven phenomenon and should be 
taken into consideration when analysing data. 
 
3.2. The influence of HPFP adsorption and absorption on the stability of spray dried 230 
BDP micro-particulates. 
After equilibration for 24 hrs in the ampoule, the spray dried microparticles of BDP were 
exposed to two cycles at a p/p0 of 0.9 HPFP. Calorimetric data for the HPFP perfusion of 
BDP are shown in Error! Reference source not found.Error! Reference source not 
found.Figure 3.  Analysis of the data suggested that the initial exothermic peak (Cycle 1) 235 
(corresponding to a change in p/p0 from 0 to 0.9) comprised of heat from three processes 
occurring simultaneously: wetting of the internal surfaces of the ampoule, wetting of the BDP 
and crystallization of the BDP. Crystallization occurs almost instantaneously, suggesting that 
HPFP takes little time to absorb and act as a plasticizer on the powder bed.  The enthalpy of 
crystallisation was obscured by the wetting of the ampoule and sample, as previously 240 
discussed by Ramos et al 2005 (27). Consequently the area under the first endotherm 
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(corresponding to a change in p/p0 from 0.9 to 0) can be added to the area under the exotherm 
to estimate the contribution of crystallization to the initial exotherm. Although the drying of a 
crystalline sample may not be technically equivalent to the wetting of an amorphous sample, 
data error can be assumed negligible. Furthermore, assuming a complete and irreversible 245 
change in the BDP sample, a second cycle can be used to assess the contribution of vial and 
powder bed to simple adsorption phenomena. 
 
In both cycles the desorption isotherms were identical, however the average net heat output 
for the initial exothermic adsorption peak was 4241.4 mJ during cycle 1 and 185.7 mJ during 250 
cycle 2, respectively, suggesting an irreversible crystallisation event had occurred in the BDP 
sample. Furthermore, the peak max occurred earlier in cycle 2 compared with the initial 
experiment suggesting that time was required for the HPFP to perfuse into the powder bed to 
drive the increase molecular mobility required for crystalisation. 
 255 
Whilst the TAM data provides useful information regarding the real-time interaction of 
fluorinated molecules with BDP, conventional thermal and x-ray data is required to confirm 
change in the physical state. Subsequently, the thermal responses of the initial spray-dried 
BDP and TAM samples after exposure to HPFP were studied using DSC and XRPD. Data 
are presented in Error! Reference source not found.Error! Reference source not 260 
found.Figure 4A and B, respectively. Partial crystallization of BDP was confirmed using 
DSC.  Spray dried BDP exhibited a crystallisation exotherm at 141.47 °C, followed by a 
melting endotherm at 211.25 °C when heated at a rate of 10 °C min−1 (Error! Reference 
source not found.Error! Reference source not found.Figure 4A-i).  This finding is in 
agreement with previous studies (23). In comparison, spray dried BDP that had been exposed 265 
to HPFP vapour exhibited a crystallization exotherm at 117.82 °C (Figure 4A-ii), followed 
by a melting endotherm at 212.49 °C.  The shift in the temperature at which crystallization 
occurs and the decrease in the heat of fusion from 46.70 Jg-1 to 17.33 Jg-1 infers that HPFP 
vapour partially crystallises BDP.  Percentage crystallinity (approximately 30.1 %) was 
calculated by dividing the measured heat of fusion by the melting enthalpy of 100% 270 
crystallized BDP (Error! Reference source not found.Error! Reference source not 
found.Figure 4A-iii) (28).  
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X-ray powder diffraction patterns further support evidence of crystallization of BDP by 
HPFP vapour.  The presence of peaks at diffraction angles 9.4°, 11.16°, 12.76°, 14.32°, 275 
15.40°, 16.72°, 18.28°, 19.4°, 19.92° and 23.52° in the XRPD pattern confirms that the raw 
material is crystalline BDP (29).  A diffuse halo was observed for the spray dried BDP 
sample, which confirmed the structure to be predominantly amorphous (23).  The peaks for 
the spray dried BDP infused with model propellant HPFP were similar to the peaks observed 
for raw BDP, however additional peaks were observed at 8.08° and 12.32° which could be 280 
attributed to inclusion of HPFP within the crystalline BDP structure (Error! Reference 
source not found.Error! Reference source not found.Figure 4B-ii). It can be concluded 
that the initial exotherm in the TAM is partially due to crystallization of the powder.  More 
detailed kinetics of the non-aqueous solution mediated transformation from amorphous to 
crystalline BDP will be achieved in future synchrotron XRPD studies using approaches 285 
recently reported for analogous aqueous solution-mediated transformations (30).  It is 
interesting to note that crystallization appears to only occur at a surface level through contact 
with HPFP vapour (Error! Reference source not found.Error! Reference source not 
found.Figure 5), which means the heat is produced from partial crystallisation and so the true 
enthalpy of crystallization cannot be calculated.  Some bridging between particles of close 290 
proximity is observed, although the majority of particles maintain their spherical morphology.  
It is difficult to ascertain whether surface crystallization impedes further entry of HPFP 
vapour into the core of the BDP particle without further investigation.  Thus, it can be 
inferred from TAM measurements, DSC and SEM that HPFP vapour does crystallize BDP 
powder, however the mechanism of crystallization appears to be one of surface nucleation.  295 
This crystallisation process is heterogeneous as it forms at the solid/gaseous interface.  This 
site then acts as a catalyst for further crystallisation. 
 
To further study the interaction of spray dried BDP micro-particles with HPFP model 
propellant organic dynamic vapour sorption (O-DVS) was utilised. In order to replicate the 300 
ITC experiment, the O-DVS was programmed to match the perfusion method in the TAM 
(Figure 3B).  It can be seen that following exposure to 90% RVP of HPFP, the mass of the 
powder immediately increased by 10%.  This is attributed to HPFP adsorption on the surface 
of the powder.  During the 3 hours period of HPFP elution, an increase in mass gain from 10 
– 12 % was observed, symptomatic of a process of continued absorption as HPFP infiltrates 305 
to the core of the particle.  The process of absorption is seen to continue during the second 
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period of exposure to HPFP, which implies absorption is not complete for a period of several 
hours.  After the introduction of dry air into the DVS chamber, 2% of mass was immediately 
lost from the sample, followed by a second slower period of mass loss from 110 % - 106 %.  
It is proposed that the initial mass loss is due to evaporation of gaseous HPFP from the 310 
surface of the BDP, and the secondary mass loss phase due to the gradual displacement of 
HPFP with nitrogen gas in the internal structure of BDP particles.  The second half of the O-
DVS cycle is marked by the reintroduction of HPFP into the chamber at 9 hours.  Although 
there is immediate mass gain, the gradient of mass increase is not as pronounced when 
compared to the first half of the O-DVS cycle.  In accordance with this, the re-introduction of 315 
nitrogen at 12 hrs results in a similar pattern of mass loss, although less significant than the 
first O-DVS cycle. This finding can be explained by observing the augmented morphology of 
the BDP surface.  Crystallisation during the first half of the O-DVS cycle can be concluded to 
have occurred on the particle surface.  It is possible that the crystalline surface acts as a 
barrier towards further HPFP penetration; it is for this reason that less HPFP is absorbed into 320 
the internal structure of the BDP particle and subsequently less HPFP released from the 
structure.   
 
The FTIR spectra of spray dried BDP is in agreement with literature, with major identifying 
bands occurring at 1730 cm-1 and 1754 cm-1, which corresponds to conjugated C=O stretch 325 
and C=O stretch for ester groups (Figure 7).  A change in the OH vibrational band 
corresponding to 3474 cm-1 appears to sharpen after exposure to HPFP (31), signifying the 
shift away from OH hydrogen bonded state towards free OH groups (32).  In accordance with 
this the separation of peaks 1751 cm-1 and 1712 cm-1 indicate a change in carbon bond 
coupling after HPFP perfusion.  However the infrared region between 800 – 1500 cm-1 330 
remains largely consistent between samples, with only peaks 1173 cm-1 and 1188 cm-1 
splitting gradually.  FTIR spectra thus highlights the bulk of the powder remains largely BDP, 
with only a fraction of the powder incorporating HPFP into the BDP matrix.  These findings 
suggest that BDP crystallization involves the formation of a clathrate structure. 
 335 
 
3.3. The influence of HPFP adsorption and absorption on the stability of spray dried 
SS micro-particulates. 
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Calorimetric data for HPFP perfusion of SS is shown in Figure 6A.  The first exotherm in the 
initial wetting phase yielded a maximum enthalpy value of 220 µW, which is due to the 340 
adsorption of HPFP onto the surface of SS and adsorption onto the internal surfaces of the 
metal ampoule.  When compared against the higher initial enthalpy of BDP, it can be inferred 
that there is a distinction between how HPFP interacts with the surface of both APIs.  The 
initial sharp peak is followed by a wide endotherm, which may be due to immediate HPFP 
evaporation from the surface of the drug particle, even though the ampoule continued to be 345 
eluted with 90% RVP HPFP. This finding was confirmed by O-DVS (Figure 6B). 
 
In general, a mass loss of more than 1% occurred during elution with nitrogen gas initially, 
which can be attributed to water evaporation. When HPFP was introduced, a gain of <1% 
suggests that HPFP began to displace nitrogen gas and possibly deposit on the surface of the 350 
SS particle.  Steady mass loss throughout the period of HPFP perfusion suggests that HPFP 
aids in the removal of remaining nitrogen within the amorphous SS particle.  During the 
second period of nitrogen gas perfusion, all HPFP gas molecules were displaced with 
nitrogen and a mass loss of ~2% occurred.  The return to baseline is governed by the speed at 
which nitrogen gas perfuses into the SS particle.  The reintroduction of HPFP vapour induced 355 
a repeat of the gas displacement cycle.  The second round of HPFP perfusion also produced a 
power-time output that retraced the initial round of perfusion, suggesting that the SS did not 
undergo any crystallization or chemical change. These observations were further confirmed 
by qualitative analysis of SEM images of the SS micro-particulates before and after perfusion 
with HPFP (Figure 8A and B, respectively) and via X-ray powder (Figure 8C); where dual 360 
broad peaks indicated an amorphous structure typical of spray dried SS (21, 33). Thus 
findings from TAM, O-DVS, SEM and XRPD suggest that SS does not readily interact with 
gaseous HPFP solvent.    
 
3.4. Characteristics of Powder Suspensions in the ‘real’ propellant HFA-227 365 
Currently, ITC O-DVS cannot operate with real HFA propellants (either in the gas or liquid 
phase). However these techniques may provide a fundamental insight into the interaction of 
API micro-particle materials with fluorinated propellants using higher molecular weight 
substitutes such as HPFP. To relate the observations reported here, the study additionally 
evaluated the stability of the spray dried amorphous BDP and SS particulates in a real HFA 370 
system using HFA 227 propellant. 
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In general, analysis of an HFA 227 pressure filled suspension of spray dried BDP micro-
particulates, by SEM, suggested induced time-dependent crystallization (Error! Reference 
source not found.Error! Reference source not found.Figure 9A-C).  Furthermore, 375 
crystallization appears to be subject to surface nucleation, as crystallization appears to have 
occurred instantaneously at multiple surface areas, which were exposed for 6 hours to HFA-
227. This particular time dependent sequence captures the process of BDP-solvate compound, 
namely a clathrate formation (11, 34). The possibility of the formation of a solvated BDP 
crystal form is likely; DVS data shows an increase in powder mass during solvation of HPFP, 380 
which suggests that HPFP solvent molecules interact with BDP molecules and are 
subsequently trapped inside a clathrate framework (Figure 3B). It is proposed that a similar 
interaction would occur in the lower molecular weight HFA 227. 
 
In comparison spray dried SS micro-particles maintained their spherical morphology with 385 
pitted surfaces after half an hour and 6 hours exposure (see supplementary data).  Minimal 
particle-particle interactions were observed after 6 hours. Such observations match those 
observed using ITC and O-DVS with HPFP as the model propellant.  
 
  390 
15 
 
4. Conclusions 
Isothermal calorimetry is a suitable technique to investigate crystallization kinetics of APIs in 
propellant systems. The early stages of BDP clathrate formation were successfully 
investigated using a surrogate propellant coupled with ITC. Similarly, the stability of the SS 
in HFA-227 was predicted using ITC experiments with surrogate propellant. This work 395 
establishes ITC as a useful diagnostic tool for predicting API stability in HFA formulations. 
The use of the ITC could be expanded to include biological and macromolecule preparations 
intended for pressurized metered dose inhalers. 
 
  400 
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Tables and Figures 
 
Table 1. Average size distributions (d0.1, d0.5 and d0.9) for spray dried SS and spray 
dried BDP 
Percentile Value Beclomethasone 
Dipropionate (µm ± StDev) 
Salbutamol Sulphate (µm ± 
StDev) 
d0.1 0.62 ± 0.01 0.8 ± 0.02 
d0.5 1.24 ± 0.01 2.95 ± 0.22 
d0.9 2.35 ± 0.07 6.12 ± 0.29 
 415 
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